Vail Scientific Inc
Vail Scientific develops non-invasive, rapid sepsis detection technology designed for point-of-care and early intervention. The company leverages exhaled nitric oxide measurement for enhanced sensitivity and speed in sepsis screening, aiming to reduce mortality rates and improve patient outcomes. Since 2019, Vail Scientific has been focused on clinical research, device innovation, and advancing toward commercialization and regulatory clearance.
Industries
Nr. of Employees
small (1-50)
Vail Scientific Inc
7800 Metro Parkway Suite 105 Bloomington, MN 55425
Patents
Apparatus and method for the determination of endothelial dysfunction and sepsis risk using nitric oxide concentrations in exhaled breath
US-12539073-B1
View Details
Apparatus and method for the determination of endothelial dysfunction and sepsis risk using nitric oxide concentrations in exhaled breath
US-12539073-B1
View DetailsProducts
Non-invasive breath-based sepsis screening device
Portable, handheld diagnostic device measuring exhaled nitric oxide for rapid, point-of-care detection of sepsis in emergency and triage settings.
Non-invasive breath-based sepsis screening device
Portable, handheld diagnostic device measuring exhaled nitric oxide for rapid, point-of-care detection of sepsis in emergency and triage settings.
Expertise Areas
- Sepsis diagnostics
- Point-of-care medical devices
- Biomarker-based screening
- Emergency medicine clinical research
Key Technologies
- Exhaled nitric oxide measurement
- Portable breath analysis
- Algorithmic clinical scoring
- Handheld diagnostic devices
News & Updates
Secured a $2.0 million investment from Exit 156 to accelerate development and commercialization of rapid sepsis detection technology.
Completed an oversubscribed funding round in August 2021 to support proof-of-concept studies and device development.
Initiated a proof-of-concept clinical study at HealthPartners to further validate sepsis detection technology.
Design News article highlighting development of portable breath analyzer for sepsis risk screening.
Announcement of strategic collaboration for redesign and manufacture of a portable sepsis detection device.
Medical Design & Outsourcing features Vail Scientific’s updated point-of-care device for sepsis detection.
Secured a $2.0 million investment from Exit 156 to accelerate development and commercialization of rapid sepsis detection technology.
Completed an oversubscribed funding round in August 2021 to support proof-of-concept studies and device development.
Initiated a proof-of-concept clinical study at HealthPartners to further validate sepsis detection technology.
Design News article highlighting development of portable breath analyzer for sepsis risk screening.
Announcement of strategic collaboration for redesign and manufacture of a portable sepsis detection device.
Medical Design & Outsourcing features Vail Scientific’s updated point-of-care device for sepsis detection.